4.7 Article

Inhibition of Indigoidine Synthesis as a High-Throughput Colourimetric Screen for Antibiotics Targeting the Essential Mycobacterium tuberculosis Phosphopantetheinyl Transferase PptT

Journal

PHARMACEUTICS
Volume 13, Issue 7, Pages -

Publisher

MDPI
DOI: 10.3390/pharmaceutics13071066

Keywords

PPTase; NRPS; indigoidine; PptT; antibiotic screening

Funding

  1. Royal Society of New Zealand Marsden Fund [VUW0901]
  2. VUW postgraduate scholarship

Ask authors/readers for more resources

This study presents a high throughput colorimetric screen for identifying inhibitors of the essential phosphopantetheinyl transferase PptT in Mycobacterium tuberculosis. The screen monitors the activation of the non-ribosomal peptide synthetase BpsA to synthesize indigoidine in vitro, using unadulterated coenzyme A. The method is sensitive, capable of distinguishing weak from strong inhibitors, and can be used to quantify inhibition levels and generate consistent EC50 data.
A recently-validated and underexplored drug target in Mycobacterium tuberculosis is PptT, an essential phosphopantetheinyl transferase (PPTase) that plays a critical role in activating enzymes for both primary and secondary metabolism. PptT possesses a deep binding pocket that does not readily accept labelled coenzyme A analogues that have previously been used to screen for PPTase inhibitors. Here we report on the development of a high throughput, colourimetric screen that monitors the PptT-mediated activation of the non-ribosomal peptide synthetase BpsA to a blue pigment (indigoidine) synthesising form in vitro. This screen uses unadulterated coenzyme A, avoiding analogues that may interfere with inhibitor binding, and requires only a single-endpoint measurement. We benchmark the screen using the well-characterised Library of Pharmaceutically Active Compounds (LOPAC(1280)) collection and show that it is both sensitive and able to distinguish weak from strong inhibitors. We further show that the BpsA assay can be applied to quantify the level of inhibition and generate consistent EC50 data. We anticipate these tools will facilitate both the screening of established chemical collections to identify new anti-mycobacterial drug leads and to guide the exploration of structure-activity landscapes to improve existing PPTase inhibitors.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available